VISEN Pharmaceuticals (2561) announced that its board of directors will hold a meeting on 12 March 2026. Key topics include reviewing and approving the financial results for the year ended 31 December 2025, along with other business matters.
According to the announcement dated 2 March 2026, the board members include one executive director, two non-executive directors, and four independent non-executive directors. The annual results will be published following the board’s approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments